• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

FDA Strategic Redeployment

<< Return to FY 2007 Budget Summary

 

What is the strategic deployment?

FDA is proposing a strategic redeployment of $52,277,000 in FY 2007 base resources.  This strategic redeployment will allow the agency to fund six critical initiatives:  pandemic preparedness, food defense, drug safety, critical path to personalized medicine, human tissues and additional budget authority to maintain animal drug and medical devices user fee programs. 

To fund these initiatives and essential infrastructure requirements at FDA, our budget reflects a strategic redeployment of resources from lower priority programs to the priority initiatives that we have proposed for FY 2007.  Our strategic redeployment will achieve program savings of $52,277,000, and thereby enable the Agency to fund new high priority initiatives. 

 

Budget Authority Offset
Program Center Field Offset Amount
Foods ($14,324,000) ($8,323,000) ($22,647,000)
Human Drugs ($5,430,000) ($1,661,000) ($7,091,000)
Biologics ($7,568,000) ($198,000) ($7,766,000)
Animal Drugs and Feeds ($1,469,000) ($1,260,000) ($2,729,000)
Devices and Radiological Health [1] $486,000 0 $486,000
NCTR ($7,033,000) -- ($7,033,000)
Other Activities ($5,497,000) -- ($5,497,000)
Total ($40,835,000) ($11,442,000) ($52,277,000)
FTE -141 -48 -189

 

Why is this redeployment necessary?

FDA determined that funding its priority initiatives required a strategic redeployment of resources from base programs and activities.  To accomplish this strategic redeployment, FDA reduced base programs to provide the necessary resources to fund the Agency's high priority initiatives.  These initiatives will provide the greatest benefit to the American public by ensuring the safety of the food supply, medical products, and human tissues, preparing for and combating the spread of the pandemic influenza outbreak, and promoting innovation in the development of new medical products that can lead to an era of personalized medicine.  A program-by-program summary of our strategic redeployment follows:

 

Foods Program

To fund FY 2007 priority initiatives such as such as food defense and pandemic influenza, FDA re-deployed resources from base programs.  To accomplish this strategic redeployment and fund new, high priority initiatives, CFSAN reductions include:  Research, Cosmetics, Dietary Supplements, Proficiency Testing, Outreach and Standard Setting, Regulatory Support, Premarket Food and Color Additives, and Food Contact Substances Notification.  The Field - Foods reductions include lower levels of effort in these activities: analysis of low-risk domestic and import samples (FDA will continue to analyze high risk samples, including those flagged by the Prior Notice Center), research related to laboratory analytical methods, compliance and recall functions and management, supervisory, and coordination personnel at multiple locations.

 

Human Drugs Program

To fund FY 2007 priority initiatives such as Drug Safety and the Critical Path to Personalized Medicine, FDA re-deployed resources from base programs.  To accomplish this strategic redeployment and fund new, high priority initiatives, Human Drugs reductions include: generic drugs research contracts, animal care contract services, research/lab scientists, laboratory upkeep, and communications, staff for FOI requests, management services, and information processing modernization for the generic drugs program. 

 

Biologics Program

To fund FY 2007 priority initiatives such as Pandemic Preparedness and the Human Tissues Initiative, FDA re-deployed resources from base programs.  To accomplish this strategic redeployment and fund new, high priority initiatives, Biologics reductions include: guidance development, early interactions with sponsors, non-emergency communications and outreach, activities related to blood and to cell and gene therapy products, and certain related post-market, safety, research, and international harmonization activities.

 

Animal Drugs and Feeds Program

To fund FY 2007 priority initiatives such as Pandemic Preparedness, FDA re-deployed resources from base programs.  To accomplish this strategic redeployment and fund new, high priority initiatives, Animal Drugs and Feeds reductions include: research, postmarket activities, and the Generally Recognized as Safe (GRAS) notification system.  

 

Field Activities Support

To fund FY 2007 priority initiatives such as Pandemic Preparedness, Food Defense, and Human Tissues Initiatives, FDA re-deployed resources from base programs.  To accomplish this strategic redeployment and fund new, high priority initiatives, ORA's Field Activities reductions include:  the analysis of domestic and import samples of food and human and veterinary drug products; inspection of preapproval and bioresearch monitoring inspections of veterinary drugs; inspections of veterinary feed manufacturers and human drugs manufacturers; regulatory research related to the development of laboratory analytical methods for foods, human drug, and animal feed products; compliance and recall functions involving food, human drugs, and animal drugs and feeds; and the management, supervisory, and coordination of personnel at multiple locations involved in the food, human drugs, and animal drug and feeds areas.   

 

National Center for Toxicological Research Program

To fund FY 2007 priority initiatives such as Food Defense, Pandemic Preparedness, and Human Tissues Initiatives, FDA re-deployed resources from base programs.  To accomplish this strategic redeployment and fund new, high priority initiatives, NCTR reductions include:  infrastructure and contract support, and research support services including animal care/diet preparation pathology and scientific information technology.  NCTR is also reducing studies in the areas of systems biology, genetic and reproductive toxicology, and rapid identification methods for biohazards.

 

Other Activities Program

To fund FY 2007 priority initiatives such as activities such as Pandemic Preparedness, Food Defense, and Drug Safety, the Other Activities program will reduce the number of the FTE through attrition, selective replacement of vacant positions, and other workforce restructuring strategies,.


[1] The Devices and Radiological Health Program received an increase to ensure that FDA maintains sufficient budget authority to comply with the Medical Device User Fee and Modernization Act [FD&C Act section 738(h)(2)(A)(ii)].